• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

镰状细胞病成人终末器官疾病聚类与早期死亡率:一项回顾性前瞻性队列研究。

Clustering of end-organ disease and earlier mortality in adults with sickle cell disease: A retrospective-prospective cohort study.

机构信息

Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Nashville, Tennesse.

Vanderbilt-Meharry Sickle Cell Disease Center of Excellence, Nashville, Tennesse.

出版信息

Am J Hematol. 2018 Sep;93(9):1153-1160. doi: 10.1002/ajh.25202. Epub 2018 Jul 30.

DOI:10.1002/ajh.25202
PMID:29981283
Abstract

Chronic end-organ complications result in morbidity and mortality in adults with sickle cell disease (SCD). In a retrospective-prospective cohort of 150 adults with SCD who received standard care screening for pulmonary function abnormalities, cardiac disease, and renal assessment from January 2003 to 2016, we tested the hypothesis that clustering of end-organ disease is common and multiple organ impairment predicts mortality. Any end-organ disease occurred in 59.3% of individuals, and 24.0% developed multiple organ (>1) end-organ disease. The number of end-organs affected was associated with mortality (P ≤ .001); 8.2% (5 of 61) of individuals with no affected end-organ, 9.4% (5 of 53) of those with 1 affected organ, 20.7% (6 of 29) of those with 2 affected end-organs, and 85.7% (6 of 7) with 3 affected end-organs died over a median follow up period of 8.7 (interquartile range 3.5-11.4) years. Of the 22 individuals who died, 77.3% had evidence of any SCD-related end-organ impairment, and this was the primary or secondary cause of death in 45.0%. SCD-related chronic impairment in multiple organs, and its association with mortality, highlights the need to understand the common mechanisms underlying chronic end-organ damage in SCD, and the urgent need to develop interventions to prevent irreversible end-organ complications in SCD.

摘要

慢性终末器官并发症导致镰状细胞病 (SCD) 成人的发病率和死亡率。在一项回顾性前瞻性队列研究中,对 2003 年 1 月至 2016 年期间接受标准护理筛查的 150 例 SCD 成人的肺功能异常、心脏疾病和肾脏评估,我们检验了以下假设:终末器官疾病的聚类是常见的,多个器官损伤预测死亡率。任何终末器官疾病的发生率为 59.3%,24.0%的患者发生多种器官(>1)终末器官疾病。受影响的终末器官数量与死亡率相关(P≤0.001);8.2%(5/61)无受影响的终末器官,9.4%(5/53)有 1 个受影响的器官,20.7%(6/29)有 2 个受影响的终末器官,85.7%(6/7)有 3 个受影响的终末器官,中位随访时间为 8.7 年(四分位距 3.5-11.4 年)。在 22 例死亡患者中,77.3%的患者有任何 SCD 相关的终末器官损伤证据,其中 45.0%的死亡是 SCD 相关的终末器官损伤的主要或次要原因。SCD 相关的多器官慢性损伤及其与死亡率的关联,突出了需要了解 SCD 慢性终末器官损伤的常见机制,并迫切需要开发干预措施来预防 SCD 中不可逆的终末器官并发症。

相似文献

1
Clustering of end-organ disease and earlier mortality in adults with sickle cell disease: A retrospective-prospective cohort study.镰状细胞病成人终末器官疾病聚类与早期死亡率:一项回顾性前瞻性队列研究。
Am J Hematol. 2018 Sep;93(9):1153-1160. doi: 10.1002/ajh.25202. Epub 2018 Jul 30.
2
Prevalence, Mortality, and Access to Care for Chronic Kidney Disease in Medicaid-Enrolled Adults With Sickle Cell Disease in California: Retrospective Cohort Study.加利福尼亚州参加医疗补助计划的镰状细胞病成年患者中慢性肾脏病的患病率、死亡率和获得治疗的情况:回顾性队列研究。
JMIR Public Health Surveill. 2024 Jul 15;10:e57290. doi: 10.2196/57290.
3
Using Machine Learning to Predict Early Onset Acute Organ Failure in Critically Ill Intensive Care Unit Patients With Sickle Cell Disease: Retrospective Study.利用机器学习预测镰状细胞病重症监护病房重症患者的早期急性器官衰竭:回顾性研究
J Med Internet Res. 2020 May 13;22(5):e14693. doi: 10.2196/14693.
4
East Mediterranean region sickle cell disease mortality trial: retrospective multicenter cohort analysis of 735 patients.东地中海地区镰状细胞病死亡率试验:735例患者的回顾性多中心队列分析
Ann Hematol. 2016 May;95(6):993-1000. doi: 10.1007/s00277-016-2655-5. Epub 2016 Apr 12.
5
Prospective evaluation of chronic organ damage in adult sickle cell patients: A seven-year follow-up study.前瞻性评估成人镰状细胞病患者的慢性器官损害:一项为期七年的随访研究。
Am J Hematol. 2017 Oct;92(10):E584-E590. doi: 10.1002/ajh.24855. Epub 2017 Jul 29.
6
Patterns of mortality in sickle cell disease in adults in France and England.法国和英国成人镰状细胞病的死亡率模式。
Hematol J. 2002;3(1):56-60. doi: 10.1038/sj.thj.6200147.
7
Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease.镰状细胞病伴限制性生理学的心肌病
JACC Cardiovasc Imaging. 2016 Mar;9(3):243-52. doi: 10.1016/j.jcmg.2015.05.013. Epub 2016 Feb 17.
8
Morbidity and mortality of sickle cell disease patients starting intermittent haemodialysis: a comparative cohort study with non- Sickle dialysis patients.镰状细胞病患者开始间歇性血液透析的发病率和死亡率:与非镰状细胞透析患者的比较队列研究。
Br J Haematol. 2016 Jul;174(1):148-52. doi: 10.1111/bjh.14040. Epub 2016 Mar 17.
9
Elevated tricuspid regurgitant jet velocity, reduced forced expiratory volume in 1 second, and mortality in adults with sickle cell disease.三尖瓣反流射流速度升高、1 秒用力呼气容积降低与成年镰状细胞病患者的死亡率。
Am J Hematol. 2017 Feb;92(2):125-130. doi: 10.1002/ajh.24598.
10
Mortality in sickle cell disease: A population-based study in an aboriginal community in the Gudalur Valley, Nilgiris, Tamil Nadu, India.镰状细胞病的死亡率:印度泰米尔纳德邦尼勒古利山谷古杜勒地区的一个原住民社区的基于人群的研究。
Pediatr Blood Cancer. 2021 Mar;68(3):e28875. doi: 10.1002/pbc.28875. Epub 2020 Dec 31.

引用本文的文献

1
Nonmyeloablative Pentostatin-Cyclophosphamide Preconditioning Improves Rates of Engraftment in Adults Undergoing Haploidentical HCT for Sickle Cell Disease.非清髓性喷司他丁-环磷酰胺预处理可提高镰状细胞病成人接受单倍体相合造血干细胞移植的植入率。
medRxiv. 2025 Sep 2:2025.08.31.25334807. doi: 10.1101/2025.08.31.25334807.
2
Cortisol in sickle cell disease: a systematic review and meta-analysis.镰状细胞病中的皮质醇:一项系统评价和荟萃分析。
Blood Adv. 2025 Aug 26;9(16):4136-4150. doi: 10.1182/bloodadvances.2024015425.
3
Selecting patients with sickle cell disease for gene addition or gene editing-based therapeutic approaches: Report on behalf of a joint EHA Specialized Working Group and EBMT Hemoglobinopathies Working Party consensus conference.
为基于基因添加或基因编辑的治疗方法选择镰状细胞病患者:代表欧洲血液学协会(EHA)专门工作组和欧洲血液与骨髓移植协会(EBMT)血红蛋白病工作组联合共识会议撰写的报告
Hemasphere. 2025 Mar 13;9(3):e70089. doi: 10.1002/hem3.70089. eCollection 2025 Mar.
4
Haploidentical Bone Marrow Transplantation for Sickle Cell Disease.单倍体相合骨髓移植治疗镰状细胞病
NEJM Evid. 2025 Mar;4(3):EVIDoa2400192. doi: 10.1056/EVIDoa2400192. Epub 2025 Feb 25.
5
Transcriptomic atlas reveals organ-specific disease tolerance in sickle cell mice.转录组图谱揭示镰状细胞病小鼠的器官特异性疾病耐受性
Blood Adv. 2025 Mar 25;9(6):1405-1419. doi: 10.1182/bloodadvances.2024013435.
6
Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease.镰状细胞病青少年和青年患者造血细胞移植与标准治疗的比较。
Blood Adv. 2025 Mar 11;9(5):955-965. doi: 10.1182/bloodadvances.2024013926.
7
Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States.Lovotibeglogene Autotemcel(Lovo-Cel)基因疗法治疗美国镰状细胞病和复发性血管阻塞性事件患者的成本效益分析。
Pharmacoeconomics. 2024 Jun;42(6):693-714. doi: 10.1007/s40273-024-01385-9. Epub 2024 Apr 29.
8
Mortality in adults with sickle cell disease: Results from the sickle cell disease implementation consortium (SCDIC) registry.镰状细胞病成人死亡率:镰状细胞病实施联合会(SCDIC)登记处的结果。
Am J Hematol. 2024 May;99(5):900-909. doi: 10.1002/ajh.27279. Epub 2024 Mar 7.
9
Evaluating self- vs interviewer-administered screening for depression in sickle cell disease.评估镰状细胞病患者中自我管理与访谈者管理的抑郁症筛查情况。
Blood Adv. 2024 Feb 13;8(3):699-702. doi: 10.1182/bloodadvances.2023012083.
10
The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally.镰状细胞病中半相合移植方案的范围:并非所有单倍体都是平等的。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):532-541. doi: 10.1182/hematology.2023000486.